 |
Partners' Directory |
| Home Search Join the Partnership Login | |
| Contact | General | Specializations in Countries | Contribution to the Global Plan | Declaration |
View this partner's profile
Organization Contact Information | |
| Name: | Tuberculosis Research Unit |
| Street 1: | Case Western Reserve University |
| Street 2: | 10900 Euclid Avenue |
| City: | Cleveland |
| Province: | Ohio |
| Post Code: | 44106-4984 |
| Country: | United States of America |
| Phone: | 2163681949 |
| Email: | whb@case.edu |
| Web Site: | http://www.tbresearchunit.org |
|
|
||||||||||||||||||||||||||||
General Information | |
| Organization Type - Primary: | Academic / Research Institution |
| Organization Type - Secondary: | None |
| Is your organization legally registered in your country: | Yes |
| Organization Reach: | International |
| Organization Description: | |
| Organization Purposes, Activities, & Funding Source The Tuberculosis Research Unit (TBRU) is an NIH-funded research contract and multi-national consortium of investigators and institutions with expertise in the areas of epidemiology, microbiology, and immunity, to conduct clinical studies on host-pathogen interactions in tuberculosis (TB). The overall goal of the clinical studies to be carried out by the TBRU is to fill critical gaps in translational TB research and to provide tools needed to advance new health care interventions in TB endemic countries. This NIH contract was initially awarded to Case Western Reserve University in 1994 and refunded again in 1999 and 2007. The formal Statement of Work, as outlined by NIH for the TBRU specific contract objectives can be provided, as needed. The epidemiologic component will provide detailed longitudinal studies in areas of high prevalence of disease. These studies will identify factors associated with disease transmission including primary infection, re-infection, re-activation, and other factors associated with increased spread of infection and expression of disease, including behavioral factors associated with compliance. A large observational cohort study with multiple subcomponent projects in immunology, genetics, microbiology, and other areas have been ongoing since 1996. The immunologic component will dissect the immune responses associated with primary infection, re-infection, latency and disease prevention and progression. Ongoing studies since 1994 are incorporated into both the epidemiologic studies as well as the clinical trials. The microbiologic component will identify the microbial factors that are associated with the various stages of clinical illness, drug targets, and potential vaccines as well as factors associated with the emergence of drug resistance. Microbiologic studies have been ongoing since 1994 are also incorporated into both the epidemiologic studies and the clinical trials. The clin |
|
| Total number of staff in your organization: | 100 + |
| Number of full-time staff who are directly involved with TB: | 100 + |
| Number of part-time staff who are directly involved with TB: | 6 - 10 |
| Number of volunteers who are directly involved with TB: | 1 - 5 |
| What is your organization's annual budget (USD) dedicated to TB? | $1 MIL-$10 MIL |
| How did you hear about the Stop TB Partnership: | Other partners |
| Why do you wish join the Stop TB Partnership: | Involvement in Stop TB Working Groups |
| Are you a member of a Stop TB national partnership: | United States of America |
| Are you in contact with your national TB programme: | Yes |
| Please tell us how your organization is contributing to your country's national TB control plan: | |
| Multidisciplinary research on the human response to M. tuberculosis impacts new TB diagnostics, drug and vaccine development required for improving TB control. | |
Geographical Reach | |
| Which country is your headquarters located in: | United States of America |
| Which WHO region is the main focus of your work: | American |
| Which countries do you do operate in: (This includes countries you are conducting activities in) |
Morocco Philippines South Africa Uganda |
Specializations | |
|
Research and Development |
Specializations in Countries | |
| Research and Development | Morocco |
| Research and Development | Philippines |
| Research and Development | South Africa |
| Research and Development | Uganda |
Contribution | |
| Please tell us how your organization will contribute to the Global Plan to Stop TB by briefly describing its involvement in any of the areas of work listed below: | |
|
TB-HIV: Immunology, microbiology and clinical trials Laboratory Strengthening: Lab. capacity in clinical immunology and mycobacteriology in sites where we work. Serve as resource for sites setting up to participate in TB research. New Diagnostics: Clinical research that may result in new diagnostic approaches. New TB Drugs: Clinical trials. New TB Vaccines: Clinical trials. Fundamental Research: Multidisciplinary (immunology, mycobacteriology, genetics, systems biology) research on the human response to M. tuberculosis in TB endemic settings. |
|
Declaration | |
| Declaration of interests: None | |
| Application date: | |
| Last updated: | May 15, 2012 |